Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Catherine A. Flynn"'
Autor:
Jorge J. Castillo, Shayna Sarosiek, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. Treon
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 927-929 (2022)
Abstract The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib
Externí odkaz:
https://doaj.org/article/2b3ae86ac79d4f00af7997d2bc26306a
Autor:
Amanda Kofides, Zachary R. Hunter, Lian Xu, Nicholas Tsakmaklis, Maria G. Demos, Manit Munshi, Xia Liu, Maria Luisa Guerrera, Carly R. Leventoff, Timothy P. White, Catherine A. Flynn, Kirsten Meid, Christopher J. Patterson, Guang Yang, Andrew R. Branagan, Shayna Sarosiek, Jorge J. Castillo, Steven P. Treon, Joshua N. Gustine
Publikováno v:
HemaSphere, Vol 5, Iss 8, p e624 (2021)
Externí odkaz:
https://doaj.org/article/24e61dfdebac48c1b54aaa8f7c982571
Autor:
Joshua N. Gustine, Shayna Sarosiek, Catherine A. Flynn, Kirsten Meid, Carly Leventoff, Timothy White, Maria Luisa Guerrera, Lian Xu, Amanda Kofides, Nicholas Tsakmaklis, Manit Munshi, Maria Demos, Christopher J. Patterson, Xia Liu, Guang Yang, Zachary R. Hunter, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo
Publikováno v:
Haematologica, Vol 107, Iss 5 (2021)
Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with prolonged treatment. We therefore evaluated the natural history and treatment outcomes in 51 WM p
Externí odkaz:
https://doaj.org/article/56e793968d144ede8278e7e6afb13222
Autor:
Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Catherine A. Flynn, Maria G. Demos, Maria L. Guerrera, Cristina Jimenez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon
Publikováno v:
HemaSphere, Vol 4, Iss 3, p e363 (2020)
Abstract. Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether ther
Externí odkaz:
https://doaj.org/article/141760b83a474b2d84cd37e9f0f50644
Autor:
Shayna Sarosiek, Joshua N. Gustine, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. Treon, Jorge J. Castillo
Publikováno v:
British Journal of Haematology. 201:897-904
Autor:
Andrew R. Branagan, Matthew M Lei, Clifton C Mo, Andrew J. Yee, Elizabeth K. O'Donnell, Jorge J. Castillo, Omar Nadeem, Noopur Raje, Steven P Treon, Paul G. Richardson, Rie Nakamoto-Matsubara, Kirsten Meid, Zachary S. Bernstein, Rebecca T. Lyons, Rakesh Verma, Zachary R Hunter, Maria Luisa Guerrera, Catherine A. Flynn, Jill N. Burke, Cynthia C. Harrington, Emerentia Agyemang, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Nora K. Horick, Shayna Sarosiek
Publikováno v:
Blood. 140:10094-10096
Autor:
Louisa Shackleton, Stephen E. Langabeer, David O’Brien, Sarah L. McCarron, Bridgette Byrne, Rupert Barry, Richard Flavin, C. Larry Bacon, Catherine M. Flynn
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
Thrombocytopenia is one of the most common hematological abnormalities observed during pregnancy, and in rare cases, this may be the first indicator of an underlying hematological malignancy. Hairy cell leukemia (HCL) is an uncommon B-cell lymphoprol
Externí odkaz:
https://doaj.org/article/0f9b759618b243999140e274ee2f9dc2
Autor:
Christopher J. Patterson, Lian Xu, Tanya Siddiqi, Maria Luisa Guerrera, Shayna Sarosiek, Zachary R. Hunter, Andrew R. Branagan, Xia Liu, Carly Leventoff, Catherine A Flynn, Ranjana H. Advani, Kirsten Meid, Nicholas Tsakmaklis, Maria Demos, Matthew S. Davids, Guang Yang, Amanda Kofides, Timothy P White, Manit Munshi, Steven P. Treon, Jorge J. Castillo, Richard R. Furman, John N. Allan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(1)
PURPOSE BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. The activity of venetocla
Autor:
Jorge J. Castillo, Shayna R. Sarosiek, Joshua N. Gustine, Catherine A. Flynn, Carly R. Leventoff, Timothy P. White, Kirsten Meid, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Zachary R. Hunter, Christopher J. Patterson, Andrew R. Branagan, Steven P. Treon
Publikováno v:
Blood Advances. 6:1015-1024
Bruton tyrosine kinase (BTK) inhibitors are the only FDA-approved treatments for Waldenström macroglobulinemia (WM). Factors prognostic of survival and predictive of response to BTK inhibitors remained to be clarified. We evaluated 319 patients with
Autor:
Nicholas Tsakmaklis, Aldo M. Roccaro, Timothy P White, Christopher J. Patterson, Guang Yang, Antonio Sacco, Xia Liu, Yang Cao, Zachary R. Hunter, Shayna Sarosiek, Carly Leventoff, Irene M. Ghobrial, Manit Munshi, Jorge J. Castillo, Lian Xu, Steven P. Treon, Catherine A Flynn, Kirsten Meid, Andrew R. Branagan, Amanda Kofides, Maria Luisa Guerrera, Maria Demos
Publikováno v:
Blood
MYD88 and CXCR4 mutations are common in Waldenström macroglobulinemia (WM). Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a phase 1 trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this first-ever study to target C